Abstract

BackgroundRheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor, anti-citrullinated protein antibodies, and bone erosions. Current therapies can compromise immunity, leading to risk of infection. The interleukin-20 receptor (IL-20R) axis comprising IL-19, IL-20, and IL-24 and their shared receptors activates tissue homeostasis processes but not the immune system. Consequently, modulation of the IL-20R axis may not lead to immunosuppression, making it an interesting drug target. We evaluated the role of the IL-20R axis in RA and associations between plasma cytokine levels and clinical disease.MethodsPlasma IL-19, IL-20, and IL-24 levels were measured in early RA patients during a treat-to-target strategy by enzyme-linked immunosorbent assays. The IL-20R1 and IL-22R1 levels in paired peripheral blood mononuclear cells and synovial fluid mononuclear cells from a different cohort of RA patients were evaluated by flow cytometry and confocal microscopy. Monocytes/macrophages were stimulated with heat-aggregated human immunoglobulin immune complexes and immune complexes containing citrullinated fibrinogen, and osteoclasts were incubated with IL-19, IL-20, and IL-24.ResultsThe plasma concentrations of IL-20 and IL-24 (but not IL-19) were increased in early RA patients compared with healthy controls (both P < 0.002) and decreased after 6 months of treatment (both P < 0.0001). The expression of IL-22R1 (but not IL-20R1) was increased on monocytes from RA synovial fluid compared with monocytes from both RA and healthy control peripheral blood. The plasma concentrations of IL-20 and IL-24 were increased in rheumatoid factor and anti-citrullinated protein antibody positive compared with negative early RA patients (all P < 0.0001). Immune complexes stimulated the production of the IL-20R cytokines by monocytes/macrophages. Increased baseline plasma concentrations of IL-20 and IL-24 were associated with Sharp-van der Heijde score progression after 24 months (Spearman’s rho = 0.19 and 0.26, both P < 0.05) in the early RA patients. The IL-22R1 was expressed by osteoclast precursors and in multinucleated osteoclasts. IL-20 and IL-24 increased the secretion of monocyte chemoattractant protein 1 by these cells.ConclusionsThis study suggests that IL-20 and IL-24 link RA-associated autoantibodies with radiographic progression via the IL-22R1. Modulation of this axis holds promise as feasible anti-erosive treatment modalities in seropositive RA.

Highlights

  • Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor, anti-citrullinated protein antibodies, and bone erosions

  • In another study population consisting of chronic RA patients with at least one swollen joint, paired synovial fluid mononuclear cells (SFMCs) and peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry and OCs were cultured from Synovial fluid mononuclear cell (SFMC) (n = 15)

  • Plasma concentrations of IL-20 and IL-24 were increased in early RA patients at baseline compared with Healthy control (HC), and decreased after 6 months of treatment Patients with early treatment naïve RA and HCs were studied to assess alterations and changes in plasma levels of the interleukin-20 receptor (IL-20R) cytokines before and after a treat-to-target strategy

Read more

Summary

Introduction

Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor, anti-citrullinated protein antibodies, and bone erosions. Current therapies can compromise immunity, leading to risk of infection. The interleukin-20 receptor (IL-20R) axis comprising IL-19, IL-20, and IL-24 and their shared receptors activates tissue homeostasis processes but not the immune system. Current therapies are aimed at halting erosive joint progression through sustained synovitis suppression. These treatments can compromise the normal immune response. This results in an increased risk of infection, which is the main concern of biological agents such as anti-tumor necrosis factor alpha (anti-TNFα) [1]. The interleukin (IL)-20 receptor (IL-20R) axis is pivotal for epithelial tissue homeostasis, but is generally not assumed to directly activate cells of the immune system as a main function [2,3,4]. The IL-20R2 subunit was identified as a novel risk locus for the development of RA [9], suggesting the IL-20R axis could be implicated in the pathogenesis of RA

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call